CL2009001191A1 - Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin. - Google Patents
Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.Info
- Publication number
- CL2009001191A1 CL2009001191A1 CL2009001191A CL2009001191A CL2009001191A1 CL 2009001191 A1 CL2009001191 A1 CL 2009001191A1 CL 2009001191 A CL2009001191 A CL 2009001191A CL 2009001191 A CL2009001191 A CL 2009001191A CL 2009001191 A1 CL2009001191 A1 CL 2009001191A1
- Authority
- CL
- Chile
- Prior art keywords
- apo2l
- drug
- prepare
- lung cancer
- treat lung
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 2
- 206010025323 Lymphomas Diseases 0.000 title abstract 2
- 101100369993 Mus musculus Tnfsf10 gene Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 201000005202 lung cancer Diseases 0.000 title abstract 2
- 208000020816 lung neoplasm Diseases 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Uso del péptido apo2l/trail porque sirve para preparar un medicamento para tratar el cáncer de pulmón y el linfoma de hodkin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12752808P | 2008-05-14 | 2008-05-14 | |
| US13004808P | 2008-05-28 | 2008-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009001191A1 true CL2009001191A1 (es) | 2010-07-02 |
Family
ID=41319333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009001191A CL2009001191A1 (es) | 2008-05-14 | 2009-05-14 | Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin. |
Country Status (3)
| Country | Link |
|---|---|
| CL (1) | CL2009001191A1 (es) |
| TW (1) | TW200950778A (es) |
| WO (1) | WO2009140469A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2519260A2 (en) * | 2009-12-31 | 2012-11-07 | Deutsches Krebsforschungszentrum | Novel modulators of trail signalling |
| PL391627A1 (pl) | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| JP5759557B2 (ja) | 2010-12-03 | 2015-08-05 | アダムド エスピー．ゼット オー．オー．Ａｄａｍｅｄ Ｓｐ．Ｚ Ｏ．Ｏ． | 抗がん融合タンパク質 |
| PL219845B1 (pl) * | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| PL394618A1 (pl) | 2011-04-19 | 2012-10-22 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| JP2014513128A (ja) * | 2011-05-03 | 2014-05-29 | ジェネンテック， インコーポレイテッド | 血管破壊剤とその使用 |
| CN102329387A (zh) * | 2011-09-23 | 2012-01-25 | 昆明理工大学 | 一种抗病毒蛋白trail114-281及其制备方法 |
| PL397167A1 (pl) | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| PL223487B1 (pl) | 2011-12-28 | 2016-10-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
| US10328056B2 (en) * | 2014-07-29 | 2019-06-25 | Alliance of Cardiovascular Researches | Priming of pancreatic tumor cells and cancer stem cells to TRAIL-induced apoptosis |
| EP3191131A4 (en) | 2014-08-21 | 2018-09-05 | The General Hospital Corporation | Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same |
| EP3389696B1 (en) | 2015-12-17 | 2024-11-27 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| EP3439687A1 (en) | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| EP3323428A1 (en) | 2016-11-17 | 2018-05-23 | CNRS Centre National de la Recherche Scientifique | Selective c-flip inhibitors as anticancer agents |
| CN109069584A (zh) * | 2017-06-29 | 2018-12-21 | 成都华创生物技术有限公司 | 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法 |
| EP4257132A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Sik3 inhibitors for treating diseases resistant to death receptor signalling |
-
2009
- 2009-05-14 TW TW098116058A patent/TW200950778A/zh unknown
- 2009-05-14 CL CL2009001191A patent/CL2009001191A1/es unknown
- 2009-05-14 WO PCT/US2009/043908 patent/WO2009140469A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009140469A3 (en) | 2010-08-26 |
| WO2009140469A2 (en) | 2009-11-19 |
| TW200950778A (en) | 2009-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009001191A1 (es) | Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin. | |
| ECSP24031979A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CL2009000545A1 (es) | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. | |
| CL2009001099A1 (es) | Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune. | |
| BR112012011086A2 (pt) | uso de betanecol para o tratamento de xerostomia | |
| HN2012001321A (es) | Analogo peptidico de oxintomodulina | |
| CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
| CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| CL2011003229A1 (es) | Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer. | |
| CL2012001405A1 (es) | Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer. | |
| AR088694A1 (es) | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| CL2009000542A1 (es) | Uso de un antagonista de c-met y egfr de formula general i para preparar un medicamento para tratar el cancer. | |
| CL2008000418A1 (es) | Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica. | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| UY30892A1 (es) | Inhibidores de la actividad akt | |
| CL2014003331A1 (es) | Formas cristalinas de un modulador de receptor de androgeno | |
| EA201200550A1 (ru) | Фармацевтические композиции, включающие bi-1356 и метформин | |
| CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
| CL2008001234A1 (es) | Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer. | |
| MX2016012368A (es) | Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r). | |
| CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| CR20120035A (es) | Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona |